{"doi":"10.1093/annonc/mdj134","title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy","abstract":null,"journal":"Annals of Oncology","year":2006,"id":616859,"datarank":9.250193396532929,"base_score":5.308267697401205,"endowment":5.308267697401205,"self_citation_contribution":0.7962401546101808,"citation_network_contribution":8.453953241922747,"self_endowment_contribution":0.7962401546101808,"citer_contribution":8.453953241922747,"corpus_percentile":null,"corpus_rank":null,"citation_count":201,"citer_count":200,"citers_with_citation_signal":175,"citers_with_endowment":175,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1590542,"name":"M. Espié","orcid":null,"position":1,"is_corresponding":false},{"id":1590543,"name":"A. Llombart","orcid":null,"position":2,"is_corresponding":false},{"id":1590544,"name":"A. Monnier","orcid":null,"position":3,"is_corresponding":false},{"id":1590545,"name":"B.L. Rapoport","orcid":null,"position":4,"is_corresponding":false},{"id":1590546,"name":"V. Stahalova","orcid":null,"position":5,"is_corresponding":false},{"id":1590541,"name":"M. Marty","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy","abstract":"<h4>Background</h4>Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among patients who might benefit. Dexrazoxane, a cardioprotective agent, has been shown to reduce the risk of anthracycline-associated cardiotoxicity when given from first dose of anthracycline. This study sought to confirm the benefit of dexrazoxane in patients at high risk of cardiotoxicity due to prior anthracycline use.<h4>Patients and methods</h4>A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles.<h4>Results</h4>Compared with those receiving anthracycline alone, patients treated with dexrazoxane experienced significantly fewer cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05). Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions.<h4>Conclusion</h4>Dexrazoxane significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen.","is_dataset_classified":null,"base_score":5.308267697401205,"endowment":5.308267697401205,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"16423847","pmcid":null,"openalex_id":"https://openalex.org/W2100912472","authors":[],"funders":[],"total_grants":0,"fwci":5.1347,"citation_percentile":0.95914656,"influential_citations":1,"citation_trend":[{"year":2012,"count":7},{"year":2013,"count":11},{"year":2014,"count":7},{"year":2015,"count":13},{"year":2016,"count":18},{"year":2017,"count":13},{"year":2018,"count":11},{"year":2019,"count":7},{"year":2020,"count":14},{"year":2021,"count":7},{"year":2022,"count":13},{"year":2023,"count":13},{"year":2024,"count":10},{"year":2025,"count":6},{"year":2026,"count":11}],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"http://www.annalsofoncology.org/article/S0923753419575615/pdf","host_type":"journal"},{"url":"http://www.annalsofoncology.org/article/S0923753419575615/pdf","host_type":"BRONZE"},{"url":"http://www.annalsofoncology.org/article/S0923753419575615/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753419575615?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753419575615?httpAccept=text/plain","host_type":"publisher"},{"url":"http://academic.oup.com/annonc/article-pdf/17/4/614/685112/mdj134.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/annonc/mdj134","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/16423847","host_type":"repository"},{"url":"http://annonc.oxfordjournals.org/cgi/content/short/mdj134v1","host_type":"repository"}],"fields_of_study":["Chemotherapy-induced cardiotoxicity and mitigation","Cancer Treatment and Pharmacology","Cancer-related cognitive impairment studies","Medicine","Adult","Aged","Anthracyclines","Antineoplastic Agents","Breast Neoplasms","Cardiotonic Agents","Female","Humans","Middle Aged","Neoplasm Metastasis","Razoxane"],"mesh_terms":["Adult","Aged","Antineoplastic Agents","Breast Neoplasms","Cardiotonic Agents","Female","Humans","Middle Aged","Neoplasm Metastasis","Razoxane","Anthracyclines"],"keywords":["Medicine","Dexrazoxane","Anthracycline","Chemotherapy","Metastatic breast cancer","Oncology","Breast cancer","Internal medicine","Phases of clinical research","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T00:07:48.834294Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}